Insider Trading
| CTOR Stock | 0.94 0.06 6.00% |
Slightly above 61% of Citius Oncology,'s investor base is looking to short. The analysis of overall sentiment of trading Citius Oncology, stock suggests that many investors are alarmed at this time. Citius Oncology,'s investing sentiment overview a quick insight into current market opportunities from investing in Citius Oncology,. Many technical investors use Citius Oncology, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Citius |
Filed transaction by CTOR Director, Officer: Chief Executive Officer. Insider Public Trading
Read at investorplace.com
 |
Citius Oncology, Fundamental Analysis
We analyze Citius Oncology,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Citius Oncology, is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Citius Oncology, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Citius Oncology, stock to make a market-neutral strategy. Peer analysis of Citius Oncology, could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics with similar companies.
Peers
Citius Oncology, Related Equities
| RUM | Rumble | 1.28 | ||||
| NTWK | NetSol Technologies | 0.75 | ||||
| EXCH | Exchange Bankshares | 0.57 | ||||
| APAM | Artisan Partners | 0.56 | ||||
| MLGF | Malaga Financial | 0.04 | ||||
| DFS | Discover Financial | 0.03 | ||||
| SPNT | Siriuspoint | 0.90 | ||||
| PRK | Park National | 1.61 |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.